Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CAEP
Cantor Equity Partners III
$10.48
-0.1%
$0.00
$10.30
$11.09
$320.48MN/A196,647 shs11,384 shs
DMAA
Drugs Made In America Acquisition
$10.28
+0.1%
$0.00
$9.95
$10.28
$299.88MN/A100,213 shs112 shs
HYAC
Haymaker Acquisition Corp. 4
$11.20
+0.1%
$0.00
$10.59
$11.20
$330.94M-0.02170,018 shs3,017 shs
NXR
Nuveen Select Tax-Free Income Portfolio 3
$16.56
$16.86
$15.69
$20.44
$216.04M0.1219,317 shs8,245 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CAEP
Cantor Equity Partners III
0.00%-0.47%-2.60%+1,048,999,900.00%+1,048,999,900.00%
DMAA
Drugs Made In America Acquisition
0.00%+0.10%+1,026,999,900.00%+1,026,999,900.00%+1,026,999,900.00%
HYAC
Haymaker Acquisition Corp. 4
0.00%+0.18%+1,119,999,900.00%+1,119,999,900.00%+1,119,999,900.00%
NXR
Nuveen Select Tax-Free Income Portfolio 3
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CAEP
Cantor Equity Partners III
N/AN/AN/AN/AN/AN/AN/AN/A
DMAA
Drugs Made In America Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
N/AN/AN/AN/AN/AN/AN/AN/A
NXR
Nuveen Select Tax-Free Income Portfolio 3
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CAEP
Cantor Equity Partners III
0.00
N/AN/AN/A
DMAA
Drugs Made In America Acquisition
0.00
N/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
0.00
N/AN/AN/A
NXR
Nuveen Select Tax-Free Income Portfolio 3
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CAEP
Cantor Equity Partners III
N/AN/AN/AN/AN/AN/A
DMAA
Drugs Made In America Acquisition
N/AN/AN/AN/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
N/AN/AN/AN/AN/AN/A
NXR
Nuveen Select Tax-Free Income Portfolio 3
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CAEP
Cantor Equity Partners III
N/AN/A0.00N/AN/AN/AN/AN/A
DMAA
Drugs Made In America Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
N/AN/A0.00N/AN/AN/AN/AN/A
NXR
Nuveen Select Tax-Free Income Portfolio 3
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CAEP
Cantor Equity Partners III
N/AN/AN/AN/AN/A
DMAA
Drugs Made In America Acquisition
N/AN/AN/AN/AN/A
HYAC
Haymaker Acquisition Corp. 4
N/AN/AN/AN/AN/A
NXR
Nuveen Select Tax-Free Income Portfolio 3
$0.643.86%N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
CAEP
Cantor Equity Partners III
230.58 millionN/AN/A
DMAA
Drugs Made In America Acquisition
229.17 millionN/AN/A
HYAC
Haymaker Acquisition Corp. 4
N/A29.55 million23.00 millionN/A
NXR
Nuveen Select Tax-Free Income Portfolio 3
N/A13.05 million12.92 millionNot Optionable

Recent News About These Companies

Kathleen L Prudhomme's Net Worth
Nuveen New York Select Tax-Free Income Portfolio
Jan. 6 select panel asks Newt Gingrich to testify
Quanex (NX) to Report Q3 Earnings: What's in the Store?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cantor Equity Partners III NASDAQ:CAEP

$10.48 -0.01 (-0.10%)
As of 04:00 PM Eastern

We are a blank check company incorporated on November 11, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any discussions, directly or indirectly, with any business combination target regarding an initial business combination with our company. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although we expect to focus on a target in an industry where we believe our management team’s and our affiliates’ expertise will provide us with a competitive advantage, including the financial services, digital assets, healthcare, real estate services, technology and software industries. Further, our efforts to identify a prospective target business will not be limited to any characteristics, although we expect to favor potential target companies with certain characteristics which include, but are not limited to, positive long term growth prospects, competitive advantages, consolidation opportunities, recurring revenue or the potential for recurring revenue, opportunities for operational improvement and attractive margins or the potential for attractive margins. Our executive offices are located New York, New York.

Drugs Made In America Acquisition NASDAQ:DMAA

$10.28 +0.01 (+0.10%)
As of 11:01 AM Eastern

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.

Haymaker Acquisition Corp. 4 NYSE:HYAC

$11.20 +0.01 (+0.09%)
As of 08/15/2025 10:34 AM Eastern

Haymaker Acquisition Corp. 4 is a blank check company. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. Haymaker Acquisition Corp. 4 is based in New York.

Nuveen Select Tax-Free Income Portfolio 3 NYSE:NXR

Nuveen Select Tax Free Income Portfolio 3 operates as a closed-end investment fund. Its primary objective is current income exempt from regular federal income tax, consistent with preservation of capital. The company was founded on May 28, 1992 and is headquartered in Chicago, IL.